Overview

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Status:
Recruiting

Trial end date:
2028-12-25

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to compare the progression-free survival (PFS) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutations when treated with poziotinib versus docetaxel.

Phase:

Phase 3

Details

Lead Sponsor:

Spectrum Pharmaceuticals, Inc

Treatments:

Docetaxel